Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma

This study is testing relacorilant — a drug that blocks the stress hormone cortisol — combined with standard chemotherapy (nab-paclitaxel and gemcitabine) as a first-line treatment for people with metastatic pancreatic cancer. **You may be eligible if...** - You have been recently diagnosed with metastatic pancreatic adenocarcinoma (within the past 6 weeks) - Your cancer is measurable on scans - You are in reasonably good physical condition - Your life expectancy is at least 3 months **You may NOT be eligible if...** - You have previously received chemotherapy for metastatic pancreatic cancer - You have serious liver, kidney, or heart problems - You are on certain medications that interact with study drugs - You have an active infection or other condition making chemotherapy unsafe Talk to your doctor to see if this trial is right for you.